{"id":{"repo_id":"utswmed","oai_identifier":"oai:utswmed-ir.tdl.org:2152.5/359"},"canonical_url":"https://search.dev.ndltd.org/etd/utswmed/oai:utswmed-ir.tdl.org:2152.5/359","repository":{"repo_id":"utswmed","name":"University of Texas Southwestern Medical Center","base_url":"https://utswmed-ir.tdl.org/server/oai/request"},"display":{"title":"Medication Adherence in Children and Adolescents with Major Depressive Disorder","abstract":"Major Depressive Disorder (MDD) is a serious psychiatric disorder in children and adolescents where antidepressant adherence remains an important issue. The present study uses electronic monitoring (Medication Event Monitoring System, APREX, Fremont, California [MEMS® caps]) to compare various methods of measuring adherence. Subjects who met the Diagnostic and Statistical Manual of Mental Disorders' (DSM-IV) criteria for MDD participated in a randomized controlled trial involving fluoxetine. A subset of patients had their medication adherence monitored for up to 12 weeks using MEMS caps, blood levels, self-report, medication diaries, physicians' estimates, and pill counts. Throughout the 12-week process, patients also completed a number of questionnaires assessing treatment expectancy, side effects, family functioning, school functioning, cognitive beliefs, depressive symptoms, and the identity of the individual(s) dispensing medication.","abstract_html":"Major Depressive Disorder (MDD) is a serious psychiatric disorder in children and adolescents where antidepressant adherence remains an important issue. The present study uses electronic monitoring (Medication Event Monitoring System, APREX, Fremont, California [MEMS® caps]) to compare various methods of measuring adherence. Subjects who met the Diagnostic and Statistical Manual of Mental Disorders' (DSM-IV) criteria for MDD participated in a randomized controlled trial involving fluoxetine. A subset of patients had their medication adherence monitored for up to 12 weeks using MEMS caps, blood levels, self-report, medication diaries, physicians' estimates, and pill counts. Throughout the 12-week process, patients also completed a number of questionnaires assessing treatment expectancy, side effects, family functioning, school functioning, cognitive beliefs, depressive symptoms, and the identity of the individual(s) dispensing medication.","abstract_has_math":false,"creators":["Sternweis, Kathryn VanArsdale"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Hughes, Carroll W."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2010,"date_issued":"2010-07-12T17:44:53Z","date_published":"2010-07-12T17:44:53Z","updated_at":"2026-07-24T05:52:26Z","subjects":["Medication Adherence","Children","Depressive Disorder, Major"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["182523596"],"render_values":[{"text":"182523596","href":null,"code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2152.5/359","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Hughes, Carroll W."]},{"key":"dc:creator","label":"Author","values":["Sternweis, Kathryn VanArsdale"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2010-07-12T17:44:53Z","2006-08-11"]},{"key":"dc:type","label":"Dc Type","values":["Thesis","Text","dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Medication Adherence","Children","Depressive Disorder, Major"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://hdl.handle.net/2152.5/359","182523596"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Major Depressive Disorder (MDD) is a serious psychiatric disorder in children and adolescents where antidepressant adherence remains an important issue. The present study uses electronic monitoring (Medication Event Monitoring System, APREX, Fremont, California [MEMS® caps]) to compare various methods of measuring adherence. Subjects who met the Diagnostic and Statistical Manual of Mental Disorders' (DSM-IV) criteria for MDD participated in a randomized controlled trial involving fluoxetine. A subset of patients had their medication adherence monitored for up to 12 weeks using MEMS caps, blood levels, self-report, medication diaries, physicians' estimates, and pill counts. Throughout the 12-week process, patients also completed a number of questionnaires assessing treatment expectancy, side effects, family functioning, school functioning, cognitive beliefs, depressive symptoms, and the identity of the individual(s) dispensing medication."]},{"key":"dc:format","label":"Dc Format","values":["Electronic","application/pdf","born digital"]},{"key":"dc:title","label":"Title","values":["Medication Adherence in Children and Adolescents with Major Depressive Disorder"]}]}],"canonical_facts":{"dc:contributor":["Hughes, Carroll W."],"dc:creator":["Sternweis, Kathryn VanArsdale"],"dc:date":["2010-07-12T17:44:53Z","2006-08-11"],"dc:description":["Major Depressive Disorder (MDD) is a serious psychiatric disorder in children and adolescents where antidepressant adherence remains an important issue. The present study uses electronic monitoring (Medication Event Monitoring System, APREX, Fremont, California [MEMS® caps]) to compare various methods of measuring adherence. Subjects who met the Diagnostic and Statistical Manual of Mental Disorders' (DSM-IV) criteria for MDD participated in a randomized controlled trial involving fluoxetine. A subset of patients had their medication adherence monitored for up to 12 weeks using MEMS caps, blood levels, self-report, medication diaries, physicians' estimates, and pill counts. Throughout the 12-week process, patients also completed a number of questionnaires assessing treatment expectancy, side effects, family functioning, school functioning, cognitive beliefs, depressive symptoms, and the identity of the individual(s) dispensing medication."],"dc:format":["Electronic","application/pdf","born digital"],"dc:identifier":["https://hdl.handle.net/2152.5/359","182523596"],"dc:language":["en"],"dc:subject":["Medication Adherence","Children","Depressive Disorder, Major"],"dc:title":["Medication Adherence in Children and Adolescents with Major Depressive Disorder"],"dc:type":["Thesis","Text","dissertation"]},"updated_at":"2026-07-24T05:52:26Z"}